The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891

The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895

Published:2023-05-16 Issue:5 Volume:30 Page:5047-5049
ISSN:1718-7729
Container-title:Current Oncology
language:en
Short-container-title:Current Oncology

Author:

Trudeau Maureen¹,Fraser Brent²

Affiliation:

1. Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada

2. CADTH, Ottawa, ON K1S 5S8, Canada

Abstract

CADTH read with interest the commentary published on 16 December 2022, entitled “Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain” [...]

Publisher

MDPI AG

Link

https://www.mdpi.com/1718-7729/30/5/380/pdf

Reference2 articles.

1. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain;Rayson;Curr. Oncol.,2022

2. The new definition of health technology assessment: A milestone in international collaboration;Oortwijn;Int. J. Technol. Assess. Health Care,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review;Cancers;2023-08-30

2. Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”;Current Oncology;2023-05-16